Orgenesis CDMO Partner Atvio Biotechnology’s CEO to Present on Roundtable at the 2018 BIO International Convention
GERMANTOWN, Md., June 04, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that their Israeli Contract Development and Manufacturing Organization (CDMO) partner, Atvio Biotechnology, will be featured on a roundtable at the 2018 BIO International Convention being held June 4 - 7 in Boston, Massachusetts. Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Officer of Atvio, will speak on the panel, “Feeding the Demand for Cell and Gene Therapy Production,” a topic recently highlighted by FDA Commissioner Scott Gottlieb.
Dr. Karnieli, who will talk on behalf of the international society for cellular therapies, and Oxford University’s, Dr. David Brindley, will discuss industry specific topics, ranging from reactions to CAR T cell approvals to different investment theses. The discussion will also cover manufacturing capability, the dilemma facing smaller pharmaceutical companies of whether to bring this in house or to outsource, and the lack of expertise within the industry.
Panel Details are as follows:
|Location:||Boston Convention & Exhibition Center at the BPI Theatre (Booth #375 on the Exhibition Floor)|
|Date & Time:||June 5th , 1 - 2 pm ET|
Vered Caplan, Chief Executive Officer of Orgenesis commented, “We look forward to having the manufacturing process brought to the forefront of the discussion regarding the cell and gene therapy space.” Ms. Caplan continued, “Our joint venture with Atvio Biotechnology and Dr. Karnieli has allowed Orgenesis to aggressively expand our CDMO capacity and capabilities to meet client demand by introducing innovative manufacturing technologies to ensure availability, scale and cost efficiency of the therapeutical products.”
About Atvio Biotechnology
Atvio’s Innovation & cGMP Center is a leading global cell therapy process innovation center with a focus on cGMP cell & gene manufacturing, process development, custom automation, viruses manufacturing, , and translation of cell therapies from lab to market. The center provides process development capabilities and expertise, custom engineering, a unique platform design, and the optimization of cells and viruses for cGMP manufacturing. The center is part of the Orgenesis Inc. global CDMO network, which includes MaSTherCell (Belgium), CureCell (Korea), and Atvio (Israel).
Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, IPCs. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Belgian subsidiary, MaSTherCell S.A., a global CDMO, Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, quality management, and assay development, MaSTherCell's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. MaSTherCell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. This integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments. For more information, visit www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our ability to successfully develop processes and tools designed to accelerate cell therapy development, reduce costs and streamline delivery of therapeutics, the market acceptance of such processes and tools, even if successfully developed, the success of our business model, our technology not functioning as expected, our ability to retain key employees, our ability to satisfy the rigorous regulatory requirements for new procedures, our competitors developing better or cheaper alternatives to our products, our ability to achieve profitability, the sufficiency of working capital and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended November 30, 2017, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.
Edison Advisors (investors)
Released June 4, 2018